WO1996010639A3 - The taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma - Google Patents

The taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma Download PDF

Info

Publication number
WO1996010639A3
WO1996010639A3 PCT/US1995/012669 US9512669W WO9610639A3 WO 1996010639 A3 WO1996010639 A3 WO 1996010639A3 US 9512669 W US9512669 W US 9512669W WO 9610639 A3 WO9610639 A3 WO 9610639A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
taga
peptic ulceration
gastric carcinoma
detecting
Prior art date
Application number
PCT/US1995/012669
Other languages
French (fr)
Other versions
WO1996010639A2 (en
Inventor
Timothy L Cover
Martin J Blaser
Harry Kleanthous
Murali K R Tummuru
Original Assignee
Univ Vanderbilt
Oravax Inc
Timothy L Cover
Martin J Blaser
Harry Kleanthous
Murali K R Tummuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69533514T priority Critical patent/DE69533514T2/en
Priority to AT95936850T priority patent/ATE276365T1/en
Priority to CZ97966A priority patent/CZ96697A3/en
Priority to EP95936850A priority patent/EP0783579B1/en
Priority to JP8512113A priority patent/JPH10509864A/en
Priority to AU38589/95A priority patent/AU703075C/en
Application filed by Univ Vanderbilt, Oravax Inc, Timothy L Cover, Martin J Blaser, Harry Kleanthous, Murali K R Tummuru filed Critical Univ Vanderbilt
Priority to NZ295297A priority patent/NZ295297A/en
Priority to MX9702335A priority patent/MX9702335A/en
Publication of WO1996010639A2 publication Critical patent/WO1996010639A2/en
Publication of WO1996010639A3 publication Critical patent/WO1996010639A3/en
Priority to FI971326A priority patent/FI971326A/en
Priority to NO971473A priority patent/NO971473L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
PCT/US1995/012669 1994-09-30 1995-09-29 THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION AND GASTRIC CARCINOMA WO1996010639A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT95936850T ATE276365T1 (en) 1994-09-30 1995-09-29 ANTIGEN FRAGMENT OF THE TAGA GENE AND METHODS FOR DETECTING THE PREDIPOSITION OF GASTIC ULCER AND GASTIC CARCINOMA
CZ97966A CZ96697A3 (en) 1994-09-30 1995-09-29 Isolated nucleic acid encoding heliobacter pylori antigen, vector in which it is comprised, purified antigenic preparation being encoded thereby, detection method of the heliobacter pylori strain presence, method of determining pre-diathesis for peptic ulcer, method of determining pre-diathesis for stomach carcinoma, heliobacter pylori mutant and heliobacter pylori strain
EP95936850A EP0783579B1 (en) 1994-09-30 1995-09-29 Antigenic fragment of the tagA gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
JP8512113A JPH10509864A (en) 1994-09-30 1995-09-29 TagA gene and method for detecting predisposition to peptic ulcer and gastric cancer
AU38589/95A AU703075C (en) 1994-09-30 1995-09-29 The tagA gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
DE69533514T DE69533514T2 (en) 1994-09-30 1995-09-29 Antigenic fragment of the tagA gene and methods for detecting the predisposition of gastric ulcer and gastric carcinoma
NZ295297A NZ295297A (en) 1994-09-30 1995-09-29 Polypeptide encoded by an isolated nucleic acid encoding 120-128 kda taga antigen of helicobacter pylori or an antigenic fragment thereof;
MX9702335A MX9702335A (en) 1994-09-30 1995-09-29 THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION AND GASTRIC CARCINOMA.
FI971326A FI971326A (en) 1994-09-30 1997-03-27 tagA gene and methods for detecting susceptibility to gastric ulcer and gastric cancer
NO971473A NO971473L (en) 1994-09-30 1997-04-01 The TagA gene and method for detecting predisposition to peptic ulceration and gastric carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,397 1994-09-30
US08/316,397 US5733740A (en) 1992-10-13 1994-09-30 Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma

Publications (2)

Publication Number Publication Date
WO1996010639A2 WO1996010639A2 (en) 1996-04-11
WO1996010639A3 true WO1996010639A3 (en) 1996-05-17

Family

ID=23228874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012669 WO1996010639A2 (en) 1994-09-30 1995-09-29 THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION AND GASTRIC CARCINOMA

Country Status (16)

Country Link
US (3) US5733740A (en)
EP (1) EP0783579B1 (en)
JP (1) JPH10509864A (en)
CN (1) CN1166858A (en)
AT (1) ATE276365T1 (en)
CA (1) CA2201353A1 (en)
CZ (1) CZ96697A3 (en)
DE (1) DE69533514T2 (en)
ES (1) ES2231792T3 (en)
FI (1) FI971326A (en)
HU (1) HUT76730A (en)
MX (1) MX9702335A (en)
NO (1) NO971473L (en)
NZ (1) NZ295297A (en)
PL (1) PL319441A1 (en)
WO (1) WO1996010639A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
DE69333110T2 (en) * 1992-03-02 2004-05-06 Chiron S.P.A. WITH THE CYTOTOXIN OF HELICOBACTER PYLORI ASSOCIATED, IMMUNODOMINANT ANTIGEN USED IN VACCINE AND FOR DIAGNOSIS
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
WO1996001272A1 (en) * 1994-07-01 1996-01-18 Rican Limited Helicobacter proteins and vaccines
EP0909323B1 (en) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
AU735391B2 (en) * 1996-11-14 2001-07-05 Human Genome Sciences, Inc. Helicobacter polypeptides and corresponding polynucleotide molecules
US6902903B1 (en) * 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
TWI237695B (en) * 1999-12-14 2005-08-11 Joy Biomedical Corp Helicobacter pylori antigens in blood
CA2458854A1 (en) * 2001-08-31 2003-03-06 Chiron Srl Helicobacter pylori vaccination
FI118061B (en) * 2001-09-24 2007-06-15 Beanor Oy Procedure and bio donor for analysis
WO2003060121A2 (en) * 2001-12-21 2003-07-24 Diadexus, Inc. Compositions and methods relating to gastric specific genes and proteins
FI115166B (en) * 2001-12-31 2005-03-15 Biofons Oy Diagnostic procedures
WO2003080840A1 (en) * 2002-03-26 2003-10-02 Peking University School Of Oncology A method of inspecting the genetic susceptibility of h.pylori related gastric carcinoma and the use of it
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
US9568471B2 (en) * 2005-01-25 2017-02-14 The Johns Hopkins University Plasmodium diagnostic assay device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
WO1994009023A1 (en) * 1992-10-13 1994-04-28 Vanderbilt University THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262156A (en) * 1991-08-12 1993-11-16 Hycor Biomedical, Inc. Antigenic compositions and their use for the detection of Helicobacter pylori
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
WO1994009023A1 (en) * 1992-10-13 1994-04-28 Vanderbilt University THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. COVACCI ET AL.: "Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and dual ulcer", PROC. NATL.ACAD SCI., vol. 90, no. 12, 15 June 1993 (1993-06-15), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 5791 - 5795 *
M.K.R. TUMMURU ET AL.: "Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: Evidence of linkage to Cytotoxin production", INFECTION AND IMMUNITY, vol. 61, no. 5, ASM,WASHINGTON,DC,US, pages 1799 - 1809 *

Also Published As

Publication number Publication date
WO1996010639A2 (en) 1996-04-11
AU703075B2 (en) 1999-03-11
EP0783579A2 (en) 1997-07-16
FI971326A (en) 1997-05-27
NO971473D0 (en) 1997-04-01
EP0783579B1 (en) 2004-09-15
US6153390A (en) 2000-11-28
ES2231792T3 (en) 2005-05-16
CZ96697A3 (en) 1997-10-15
DE69533514D1 (en) 2004-10-21
NO971473L (en) 1997-05-29
PL319441A1 (en) 1997-08-04
NZ295297A (en) 1999-03-29
CA2201353A1 (en) 1996-04-11
CN1166858A (en) 1997-12-03
AU3858995A (en) 1996-04-26
US5733740A (en) 1998-03-31
US5876943A (en) 1999-03-02
HUT76730A (en) 1997-11-28
DE69533514T2 (en) 2005-09-15
ATE276365T1 (en) 2004-10-15
FI971326A0 (en) 1997-03-27
JPH10509864A (en) 1998-09-29
MX9702335A (en) 1997-10-31

Similar Documents

Publication Publication Date Title
WO1996010639A3 (en) The taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
AU2706384A (en) Colorimetric immunoassay on solid surface
GR850899B (en)
EP0325045A3 (en) Immunoassay method for detecting antigens
AU559966B2 (en) Assaying antibody-antigen reactions
NO962084L (en) DNA sequence encoding a BMP receptor
ES483606A1 (en) Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination.
EP0346119A3 (en) Anti-fc assay for detection of antibodies
KR930016439A (en) CENP-B Antigen Determination Unit
ES484166A1 (en) Method and reagent for the detection and the determination of complement-binding antibodies.
DE69829587D1 (en) NUCLEIC ACID MOLECULES CORRELATING WITH THE WEAK RHESUS-D PHENOTYP
EP0271810A3 (en) Immunological determination of free human protein s and c4bp-protein s complex
CA2213083A1 (en) Detection of antibody production
EP1048949A3 (en) Template and method of use
EP0268465A3 (en) Method for detecting the presence of a plant antigen in a plant
ES2001626A6 (en) Monoclonal antibodies.
EP0250119A3 (en) Atherosclerotic anti-idiotype antibody immunoassay and reagents
Cover et al. Taga gene and methods for detecting predisposition to peptic ulceration
EP0219279A3 (en) A reagent for detection and measurement of acetaldehyde-protein condensates in a fluid, together with its preparation and method of use
EP0248630A3 (en) Atherosclerotic plaque antigen immunoassay
EP0959132A4 (en) Nucleic acid encoding receptor type protein kinase
Caton et al. Immunosubtractive Electrophoresis on Gradient Polyacrylamide Gels
Fluyer Rapid coagglutination method for typing staphylococcal A and B type enterotoxins using sensitized antienterotoxic staphylococci antibodies containing protein A.
EP0259773A3 (en) A novel antibody specific for a cancer antigen
EP0376707A3 (en) Enzyme quantitation wicking assay

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95196382.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WD Withdrawal of designations after international publication

Free format text: US

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 53 AND 55,DESCRIPTION,AND PAGES 1/4-4/4,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2201353

Country of ref document: CA

Ref document number: 2201353

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 971326

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: PV1997-966

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/002335

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 295297

Country of ref document: NZ

Ref document number: 1995936850

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995936850

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-966

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1997-966

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1995936850

Country of ref document: EP